Navigation Links
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Date:1/14/2008

nical data and patient and physician preference. We are convinced that physicians and patients will continue to choose PEGASYS/ribavirin combination therapy based on positive experience and sound clinical evidence," said George Abercrombie, President and CEO, Hoffmann-La Roche. "Our current focus at Roche is on advancing the treatment of hepatitis C by optimizing doses and duration of PEGASYS/ribavirin in patients with unmet medical need, while developing new compounds that have the potential to offer a successful outcome to even more patients."

Roche believes that it is critical for patients and physicians to receive complete information to fully understand the results of "IDEAL," so that treatment decisions can be based on sound scientific data.

Please see below for additional information about the "IDEAL" trial, Roche and PEGASYS, including important safety information.

"IDEAL" Trial Design Issues

* Starting doses of ribavirin were different in the Peg-Intron and

PEGASYS arms of the study

* The design calls for a more drastic ribavirin dose reduction for side

effect management in most patients in the PEGASYS arm compared to

patients in the Peg-Intron arms; in some cases, ribavirin dose

reductions for patients in the PEGASYS arm were three times greater

than for patients in the Peg-Intron arms. This is important because a

substantial number of patients being treated for hepatitis C require

their ribavirin dose to be reduced to manage side effects, and this

could have an impact on the efficacy of the regimen

* The PEGASYS arm was not blinded, meaning that patients and physicians

knew which treatment was being administered. Many comparative studies

are blinded to ensure that bias does not compromise the results

* Erythropoetin (EPO) is a medication that is often given to treat

ribavirin-related anemia and help pat
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
2. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
3. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
4. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
11. Schering-Plough Reports Top-Line Results of the IDEAL Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Unichem Pharmaceuticals ( USA ), Inc. ... 25 mg 1000-count bottle to the consumer level. This ... to the identification of a Clopidogrel tablet found in ... risk associated with mistakenly taking a Clopidogrel tablet instead ... experiencing Clopidogrel,s side effects which include bleeding and/or bruising. ...
(Date:7/30/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced the ... of Warburg Pincus LLC, to the Amgen Board of Directors. ... Hassan and the deep, global experience he brings in ... A. Bradway , chairman and chief executive officer of Amgen. "Fred,s ... Amgen well." Mr. Hassan has been Partner and ...
(Date:7/30/2015)...  Growth of the U.S. nonprescription market is primarily ... users to the OTC market. Due to an increasingly ... switch activity over the next five years with several ... brands entering the market into existing categories. ... (even those with low to moderate likelihood), the market ...
Breaking Medicine Technology:Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... Systems Ltd. (Nasdaq: DHRM ) ("Dehaier" or ... marketing and sale of medical devices and homecare medical ... Weibing Yang as and Dr. Genhui Chen directors of ... fills the vacancy resulting from the resignation of Ms. ...
...  Researchers have published the largest single patient population ... patients with retrievable inferior vena cava (IVC) filters—devices ... the lungs. This study, which is important for ... existing guidelines developed by the Society of Interventional ...
Cached Medicine Technology:Dehaier Medical Announces Changes to Board of Directors 2Dehaier Medical Announces Changes to Board of Directors 3IVC Filters: Society of Interventional Radiology Leads in Patient Care, Safety, Research 2IVC Filters: Society of Interventional Radiology Leads in Patient Care, Safety, Research 3IVC Filters: Society of Interventional Radiology Leads in Patient Care, Safety, Research 4
(Date:7/31/2015)... VA (PRWEB) , ... July 31, 2015 , ... ... is a one-day event geared to patients and family members, medical professionals, and ... and regional mesothelioma experts. The conference is a collaborative effort between the Mesothelioma ...
(Date:7/31/2015)... ... July 31, 2015 , ... Creating one of the most ... pursuit of a visionary image that goes beyond the boundaries of fertility medicine. ... has reached extraordinary heights with dependable patient support, affordable treatments, unending hope, and high ...
(Date:7/31/2015)... ... July 31, 2015 , ... Girl Scouts of Historic ... across Georgia through the Girl Scout "Be a Friend First" program. Representatives from Peach ... 30. , “Peach State Health Plan and our parent company, Centene Corporation, are ...
(Date:7/31/2015)... , ... July 31, 2015 , ... The Mount Sinai ... research projects that evaluate the potential of related, experimental treatments. The collaboration moves into ... Health to award Columbia Care one of five state licenses to produce and dispense ...
(Date:7/31/2015)... ... , ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company based in ... announces it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to use a ... MaxLife will grant 100% of the money raised to BioViva to help bring pioneering ...
Breaking Medicine News(10 mins):Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 3Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3
... A new study has revealed that one in ten people ... obesity. Earlier research that located the gene variant and // ... it was still ambiguous, whether people without the gene variant ... the link and understand it better, the researchers targeted the ...
... A research symposium titled ‘Challenging Intellectual Property’ will be ... York.// ,The Symposium will look into the ... of knowledge production in economic development. It will also ... on the table, desirous of bringing a change in ...
... famous saying that women buy for fun while men buy ... women may have more foot-healthy and comfortable// options this spring. ... heels, flat shoes and wedge heels. ,Dr. ... at Baylor University Medical Center at Dallas and president of ...
... medical services in Andhra Pradesh came to a ... strike enters the second day. ,Patients had ... services. Patients seeking immediate medical assistance had to ... at the Osmania General Hospital and the Gandhi ...
... Surgeons have now found a new surgical approach termed ... involuntary loss of urine//. It is a post operative ... a condition in which the vagina and the neighboring ... ,Most women who undergo the pelvic surgery are ...
... mistakes but what matters to the brain is the severity ... that is committed// by a person affects the brain. University ... human brain the instant a costly mistake occurs. Dr. Stephan ... the research said that the experiment was carried on to ...
Cached Medicine News:Health News:Doctors Strike In Andhra Enters The Second Day 2Health News:Two-In One Approach To Prevent Incontinence After Prolapse Surgery 2
... Reusable Purstring Device for use ... Biofragmentable Anastomosis Ring)., ,The ... intestinal, colorectal and esophageal surgery ... string sutures and is intended ...
The Auto Suture™ EEA™ 34mm reusable stainless steel sizer has application in intestinal, colorectal and esophageal surgery to help evaluate the diameter of tubular structures....
... Scantibodies Calcitonin Immunoassay is a two-site immunoradiometric ... Two different goat polyclonal antibodies to human ... to be specific for well-defined regions on ... determination of Calcitonin in human serum. ...
Fully automated Chemiluminescence assay for the measurement of calcitonin hormone in serum....
Medicine Products: